Pfizer Inc (PFE – Q1FY20) – New Pfizer – Biopharma business with key growth drivers will create long-term growth.

in , on July 23, 2020

Pfizer and the German biotech company, BioNTech, has entered into a global collaboration agreement to co-develop the potential first-in-class mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection. It received regulatory approval from German authority Paul-Ehrlich- Institut to commence the first clinical trial for COVID-19 vaccine candidates in Germany, and the first patient has already been dosed.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q1FY20 Results – Overview
– Q1FY20 – Segment Performance
– Q1FY20 – Product Developments
– FY20 Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

Release Information

  • Released

    July 23, 2020

  • Last Updated

    July 24, 2020